|
1
|
Kalisz K, Alessandrino F, Beck R, Smith D,
Kikano E, Ramaiya NH and Tirumani SH: An update on burkitt
lymphoma: A review of pathogenesis and multimodality imaging
assessment of disease presentation, treatment response, and
recurrence. Insights Imaging. 10:562019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tursynbay Y, Zhang J, Li Z, Tokay T,
Zhumadilov Z, Wu D and Xie Y: Pim-1 kinase as cancer drug target:
An update. Biomed Rep. 4:140–146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bachmann M and Möröy T: The
serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 37:726–730.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mondello P, Cuzzocrea S and Mian M: Pim
kinases in hematological malignancies: Where are we now and where
are we going? J Hematol Oncol. 7:952014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Panchal NK and Sabina EP: A
serine/threonine protein PIM kinase as a biomarker of cancer and a
target for anti-tumor therapy. Life Sci. 255:1178662020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Magnuson NS, Wang Z, Ding G and Reeves R:
Why target PIM1 for cancer diagnosis and treatment? Future Oncol.
6:1461–1478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Macdonald A, Campbell DG, Toth R,
McLauchlan H, Hastie CJ and Arthur JS: Pim kinases phosphorylate
multiple sites on Bad and promote 14-3-3 binding and dissociation
from Bcl-XL. BMC Cell Biol. 7:12006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ionov Y, Le X, Tunquist BJ, Sweetenham J,
Sachs T, Ryder J, Johnson T, Lilly MB and Kraft AS: Pim-1 protein
kinase is nuclear in Burkitt's lymphoma: Nuclear localization is
necessary for its biologic effects. Anticancer Res. 23:167–178.
2003.PubMed/NCBI
|
|
9
|
Forshell LP, Li Y, Forshell TZ, Rudelius
M, Nilsson L, Keller U and Nilsson J: The direct Myc target Pim3
cooperates with other Pim kinases in supporting viability of
Myc-induced B-cell lymphomas. Oncotarget. 2:448–460. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McBride A, Trifilio S, Baxter N, Gregory
TK and Howard SC: Managing tumor lysis syndrome in the era of novel
cancer therapies. J Adv Pract Oncol. 8:705–720. 2017.PubMed/NCBI
|
|
11
|
Zemskova M, Sahakian E, Bashkirova S and
Lilly M: The PIM1 kinase is a critical component of a survival
pathway activated by docetaxel and promotes survival of
docetaxel-treated prostate cancer cells. J Biol Chem.
283:20635–20644. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matou-Nasri S, Rhaban Z, Al-Baijan H,
Al-Eidi H, Yahya WB, Al Abdulrahman A, Almobadel N, Alsubeai M, Al
Ghamdi S, Alaskar A, et al: CD95-mediated apoptosis in Burkitt's
lymphoma B-cells is associated with Pim-1 down-regulation. Biochim
Biophys Acta Mol Basis Dis. 1863:239–252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peltola KJ, Paukku K, Aho TL, Ruuska M,
Silvennoinen O and Koskinen PJ: Pim-1 kinase inhibits
STAT5-dependent transcription via its interactions with SOCS1 and
SOCS3. Blood. 103:3744–3750. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aho TL, Sandholm J, Peltola KJ, Mankonen
HP, Lilly M and Koskinen PJ: Pim-1 kinase promotes inactivation of
the pro-apoptotic Bad protein by phosphorylating it on the Ser112
gatekeeper site. FEBS Lett. 571:43–49. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen LS, Redkar S, Taverna P, Cortes JE
and Gandhi V: Mechanisms of cytotoxicity to Pim kinase inhibitor,
SGI-1776, in acute myeloid leukemia. Blood. 118:693–702. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shah N, Pang B, Yeoh KG, Thorn S, Chen CS,
Lilly MB and Salto-Tellez M: Potential roles for the PIM1 kinase in
human cancer-a molecular and therapeutic appraisal. Eur J Cancer.
44:2144–2151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morishita D, Katayama R, Sekimizu K,
Tsuruo T and Fujita N: Pim kinases promote cell cycle progression
by phosphorylating and down-regulating p27Kip1 at the
transcriptional and posttranscriptional levels. Cancer Res.
68:5076–5085. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ouhtit A, Gupta I, Muzumdar S,
Shanmuganathan S and Tamimi Y: Understanding the functional
discrepancy of Pim-1 in cancer. Front Biosci (Elite Ed). 7:208–214.
2015.PubMed/NCBI
|
|
21
|
Luszczak S, Kumar C, Sathyadevan VK,
Simpson BS, Gately KA, Whitaker HC and Heavey S: PIM kinase
inhibition: Co-targeted therapeutic approaches in prostate cancer.
Signal Transduct Target Ther. 5:72020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blanco-Aparicio C and Carnero A: Pim
kinases in cancer: Diagnostic, prognostic and treatment
opportunities. Biochem Pharmacol. 85:629–643. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Song M, Kundu JK, Lee MH and Liu
ZZ: PIM kinase as an executional target in cancer. J Cancer Prev.
23:109–116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheney IW, Yan S, Appleby T, Walker H, Vo
T, Yao N, Hamatake R, Hong Z and Wu JZ: Identification and
structure-activity relationships of substituted pyridones as
inhibitors of Pim-1 kinase. Bioorg Med Chem Lett. 17:1679–1683.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jie W, He QY, Luo BT, Zheng SJ, Kong YQ,
Jiang HG, Li RJ, Guo JL and Shen ZH: Inhibition of Pim-1 attenuates
the proliferation and migration in nasopharyngeal carcinoma cells.
Asian Pac J Trop Med. 5:645–650. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pogacic V, Bullock AN, Fedorov O,
Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S and
Schwaller J: Structural analysis identifies
imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro
antileukemic activity. Cancer Res. 67:6916–6924. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu Z and Xu S: ERK1/2 MAP kinases in cell
survival and apoptosis. IUBMB Life. 58:621–631. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee S, Rauch J and Kolch W: Targeting MAPK
signaling in cancer: Drug resistance and sensitivity. Int J Mol
Sci. 21:11022020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Anderson PD, Luo W, Gius D, Roh M
and Abdulkadir SA: Pim1 kinase is required to maintain
tumorigenicity in MYC-expressing prostate cancer cells. Oncogene.
31:1794–1803. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aziz AR, Farid S, Qin K, Wang H and Liu B:
PIM kinases and their relevance to the PI3K/Akt/mTOR pathway in the
regulation of ovarian cancer. Biomolecules. 8:72018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Warfel NA and Kraft AS: PIM kinase (and
Akt) biology and signaling in tumors. Pharmacol Ther. 151:41–49.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brunen D, García-Barchino MJ, Malani D,
Basheer NJ, Lieftink C, Beijersbergen RL, Murumägi A, Porkka K,
Wolf M, Zwaan CM, et al: Intrinsic resistance to PIM kinase
inhibition in AML through p38α-mediated feedback activation of mTOR
signaling. Oncotarget. 7:37407–37419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bhardwaj V and He J: Reactive oxygen
species, metabolic plasticity, and drug resistance in cancer. Int J
Mol Sci. 21:34122020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zha J, Harada H, Yang E, Jockel J and
Korsmeyer SJ: Serine phosphorylation of death agonist BAD in
response to survival factor results in binding to 14-3-3 Not
BCL-X(L). Cell. 87:619–628. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lilly M, Sandholm J, Cooper JJ, Koskinen
PJ and Kraft A: The PIM-1 serine kinase prolongs survival and
inhibits apoptosis-related mitochondrial dysfunction in part
through a bcl-2-dependent pathway. Oncogene. 18:4022–4031. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gu JJ, Wang Z, Reeves R and Magnuson NS:
PIM1 phosphorylates and negatively regulates ASK1-mediated
apoptosis. Oncogene. 28:4261–4271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nguyen L, Papenhausen P and Shao H: The
role of c-MYC in B-cell lymphomas: Diagnostic and molecular
aspects. Genes (Basel). 8:1162017. View Article : Google Scholar : PubMed/NCBI
|
